Advanced Life Sciences Holdings, Inc. (ADLS) SEC Filing 10-K Annual report for the fiscal year ending Friday, December 31, 2010

Advanced Life Sciences Holdings, Inc.

CIK: 1322734 Ticker: ADLS

Exhibit 99.1


1440 Davey Road

Woodridge, IL 60517

(Phone) 630.739.6744

(Fax) 630.739.6754


March 24, 2011


Company Contact: John Flavin 630-754-4343



Advanced Life Sciences Announces 2010 Fourth Quarter and

Full Year Financial Results and Reverse Stock Split


CHICAGO, IL, March 24, 2011/PRNewswire/: —

Advanced Life Sciences Holdings, Inc. (OTCBB: ADLS.OB), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2010 and the approval of a 1-for-30 reverse stock split of the Company’s issued and outstanding common stock.


Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences, commented: “During the fourth quarter, we continued to make progress toward our strategic objectives including the Restanza community acquired bacterial pneumonia (CABP) program and biodefense initiatives. Since the completion of our Agreement with the United States Food and Drug Administration (FDA) for the Special Protocol Assessment (SPA), we have discussed the Restanza opportunity with several potential strategic partners. Their views match that of ours in that there is an urgent need for new antibiotics that work through novel mechanisms of action, and that there is an alarming dearth of late-stage compounds that represent real partnering opportunities for companies that need to expand their antibiotic franchises. They also recognize that the regulatory landscape has shifted and companies developing antibiotics need to deal with the new set of guidelines.  They believe that we have made significant progress in defining the new environment through our work with the FDA. We are hopeful that we will be able to convert this interest into a meaningful collaboration.”


“As announced earlier this year, the Company has engaged in a strategic alternatives review process.  While we continue to take steps to improve the financial standing of our Company, we believe that a potential strategic transaction, partnership or acquisition will be in the best interest of all our shareholders,” said Dr. Flavin. “In the meantime, we will continue to advance our discussions and opportunities to work with the US Government regarding Restanza’s potential in biodefense and global health.”


The net loss allocable to common shareholders for the three months ended December 31, 2010 was $3.3 million or ($0.01) per share compared to a net loss allocable to common shareholders of $1.5 million or ($0.02) per share for the three months ended December 31, 2009. All share and per share information is presented on a pre-split basis. The increase in the net loss for the quarter is primarily due to a non-cash impairment charge which was partially offset by reduced salary and benefit costs and other operating expenses associated with the development of the Company’s lead antibiotic, Restanza.


Cash used for operating activities during the quarter was approximately $1.0 million. In the fourth quarter, the Company raised approximately $0.8 million in proceeds through the use of a Standby Equity Distribution Agreement and made a $0.4 million commercial loan principal payment to further reduce outstanding debt. The Company ended the year with cash totaling approximately $0.2 million. Cash used for operating activities for the full year was approximately $6.4 million.



The following information was filed by Advanced Life Sciences Holdings, Inc. (ADLS) on Thursday, March 24, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Advanced Life Sciences Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advanced Life Sciences Holdings, Inc..


Assess how Advanced Life Sciences Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advanced Life Sciences Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2011 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ADLS
CIK: 1322734
Form Type: 10-K Annual Report
Accession Number: 0001047469-11-002603
Submitted to the SEC: Thu Mar 24 2011 2:54:46 PM EST
Accepted by the SEC: Thu Mar 24 2011
Period: Friday, December 31, 2010
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: